Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Novo Nordisk A/S (NVO) had Cost of Goods Sold of $2.13B for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$15.16B |
|
$7.60B |
|
|
Cost of Goods Sold |
$2.13B |
$13.03B |
|
$5.83B |
|
$9.34B |
|
$399.96M |
|
$9.74B |
|
$9.74B |
|
$7.60B |
|
$7.60B |
|
$7.60B |
|
$7.60B |
|
$9.34B |
|
$9.89B |
|
4.44B |
|
4.45B |
|
$1.71 |
|
$1.71 |
|
| Balance Sheet Financials | |
$27.77B |
|
$34.45B |
|
$59.81B |
|
$87.57B |
|
$35.26B |
|
$18.66B |
|
$20.51B |
|
$55.77B |
|
$31.80B |
|
$11.46B |
|
$31.80B |
|
-- |
|
| Cash Flow Statement Financials | |
$3.77B |
|
$-1.83B |
|
$-2.73B |
|
$4.14B |
|
$3.31B |
|
$-835.77M |
|
-- |
|
$-5.53B |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.79 |
|
-- |
|
-- |
|
0.37 |
|
0.72 |
|
85.96% |
|
61.57% |
|
61.57% |
|
-- |
|
64.21% |
|
50.15% |
|
$2.00B |
|
-- |
|
-- |
|
-- |
|
0.17 |
|
0.26 |
|
0.97 |
|
93.20 |
|
23.91% |
|
66.38% |
|
8.68% |
|
15.07% |
|
-- |
|
$0.45 |
|
$0.85 |
|